Maha FDA Cancels Cipla Pharma Licence Over Misbranded Drug

The Maharashtra Food and Drug Administration (FDA) has issued a fresh order cancelling Cipla Pharma and Life Sciences' licence to sell and distribute medicines, alleging that the company misbranded its combination drug Reactin Plus.